Compare CRNX & FIZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | FIZZ |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2018 | 1994 |
| Metric | CRNX | FIZZ |
|---|---|---|
| Price | $83.99 | $31.60 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $76.75 | $35.00 |
| AVG Volume (30 Days) | ★ 6.8M | 537.7K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.96 |
| Revenue | $1,039,000.00 | ★ $1,180,552,000.00 |
| Revenue This Year | $720.10 | $0.14 |
| Revenue Next Year | $184.67 | $3.33 |
| P/E Ratio | ★ N/A | $16.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $30.01 |
| 52 Week High | $84.00 | $46.99 |
| Indicator | CRNX | FIZZ |
|---|---|---|
| Relative Strength Index (RSI) | 90.37 | 44.79 |
| Support Level | $43.40 | $30.51 |
| Resistance Level | $84.00 | $35.84 |
| Average True Range (ATR) | 0.19 | 0.96 |
| MACD | -1.64 | 0.16 |
| Stochastic Oscillator | 71.70 | 45.38 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).